Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Fromm

Showing results (91-100 of 105) with videos related to

Pageof 11
Sort By:
Practical Radiation Oncology|October 5, 2019
Impact of Double- or Triple-Hit Pathology on Rates and Durability of Radiation Therapy Response Among Patients With Relapsed or Refractory Large B-Cell LymphomaAileen Kim, Philip Stevenson, Ryan D Cassaday, et al.
Journal of Human Immunity|May 6, 2026
X-linked SEPTIN6-related congenital neutropenia and B cell deficiencyLauren M Gunderman, Aleksandra Petrovic, Ingrid Lundgren, et al.
British Journal of Haematology|February 8, 2020
Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapyStephen D Smith, Brian G Till, Mazyar S Shadman, et al.
Blood Advances|October 21, 2020
Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenström macroglobulinemiaJorge J Castillo, Edward N Libby, Stephen M Ansell, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 5, 2023
Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-UpCarrie Ho, Ajay K Gopal, Brian G Till, et al.
Blood|June 9, 2018
Mass cytometry of Hodgkin lymphoma reveals a CD4<sup>+</sup> regulatory T-cell-rich and exhausted T-effector microenvironmentFathima Zumla Cader, Ron C J Schackmann, Xihao Hu, et al.
Blood Advances|November 17, 2022
Efficacy, safety, and molecular response predictors of oral ixazomib and short-course rituximab in untreated iNHLSolomon A Graf, Ryan C Lynch, Chaitra S Ujjani, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 27, 2009
Mutations in a gene encoding a midbody kelch protein in familial and sporadic classical Hodgkin lymphoma lead to binucleated cellsStephen J Salipante, Matthew E Mealiffe, Jeremy Wechsler, et al.
Head & Neck|April 25, 2025
Dual PD-1 and CTLA4 Immune Checkpoint Blockade and Hypofractionated Radiation in Patients With Advanced Salivary Gland CancersCristina P Rodriguez, Qian Vicky Wu, Kevin Ng, et al.
The Lancet. Haematology|July 30, 2021
Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 studyRyan C Lynch, Ryan D Cassaday, Stephen D Smith, et al.
Pageof 11

Showing results (91-100 of 105) with videos related to

Sort By:
Pageof 11
Practical Radiation Oncology|October 5, 2019
Impact of Double- or Triple-Hit Pathology on Rates and Durability of Radiation Therapy Response Among Patients With Relapsed or Refractory Large B-Cell LymphomaAileen Kim, Philip Stevenson, Ryan D Cassaday, et al.
Journal of Human Immunity|May 6, 2026
X-linked SEPTIN6-related congenital neutropenia and B cell deficiencyLauren M Gunderman, Aleksandra Petrovic, Ingrid Lundgren, et al.
British Journal of Haematology|February 8, 2020
Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapyStephen D Smith, Brian G Till, Mazyar S Shadman, et al.
Blood Advances|October 21, 2020
Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenström macroglobulinemiaJorge J Castillo, Edward N Libby, Stephen M Ansell, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 5, 2023
Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-UpCarrie Ho, Ajay K Gopal, Brian G Till, et al.
Blood|June 9, 2018
Mass cytometry of Hodgkin lymphoma reveals a CD4<sup>+</sup> regulatory T-cell-rich and exhausted T-effector microenvironmentFathima Zumla Cader, Ron C J Schackmann, Xihao Hu, et al.
Blood Advances|November 17, 2022
Efficacy, safety, and molecular response predictors of oral ixazomib and short-course rituximab in untreated iNHLSolomon A Graf, Ryan C Lynch, Chaitra S Ujjani, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 27, 2009
Mutations in a gene encoding a midbody kelch protein in familial and sporadic classical Hodgkin lymphoma lead to binucleated cellsStephen J Salipante, Matthew E Mealiffe, Jeremy Wechsler, et al.
Head & Neck|April 25, 2025
Dual PD-1 and CTLA4 Immune Checkpoint Blockade and Hypofractionated Radiation in Patients With Advanced Salivary Gland CancersCristina P Rodriguez, Qian Vicky Wu, Kevin Ng, et al.
The Lancet. Haematology|July 30, 2021
Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 studyRyan C Lynch, Ryan D Cassaday, Stephen D Smith, et al.
Pageof 11